Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorazepam + diphenhydramine + haloperidol gel
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Topical, Transdermal
01
Overview
A compounded topical gel containing lorazepam, diphenhydramine, and haloperidol. It is primarily used in hospice and palliative care settings for the management of nausea, vomiting, anxiety, agitation, and terminal delirium. The gel is applied topically with the intention that the medications will be absorbed transdermally, though clinical studies have questioned its efficacy, particularly regarding the absorption of lorazepam and haloperidol components.
- Other names
- ABH gelB52B-52B 52
02
Targets
DRD2 (Dopamine D2 Receptor)GABRR (GABA-A receptor subunit rho)HRH1 (Histamine H1 Receptor)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on lorazepam + diphenhydramine + haloperidol gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorazepam + diphenhydramine + haloperidol gel.